Cengild Medical Bhd (XKLS:0243) EBIT: RM13.76 Mil (TTM As of Mar. 2026)


XKLS:0243 Cengild Medical Bhd XKLS:0243
67 GF Score
Price RM0.20
GF Value RM0.29
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cengild Medical Bhd EBIT?

Cengild Medical Bhd XKLS:0243 67 EBIT is RM13.76 Mil as of Mar. 2026. GuruFocus rates XKLS:0243 with a GF Score™ of 67/100 and a GF Value™ of RM0.29 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Cengild Medical Bhd's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was RM2.85 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was RM13.76 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cengild Medical Bhd's annualized ROC % for the quarter that ended in Mar. 2026 was 4.32%. Cengild Medical Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.31%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cengild Medical Bhd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.96%.

Cengild Medical Bhd  (XKLS:0243) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cengild Medical Bhd's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=11.02 * ( 1 - 41.96% )/( (142.861 + 152.915)/ 2 )
=6.396008/147.888
=4.32 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=218.069 - 17.494 - ( 65.45 - max(0, 19.879 - 77.593+65.45))
=142.861

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=217.91 - 14.738 - ( 55.387 - max(0, 17.148 - 67.405+55.387))
=152.915

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Cengild Medical Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=11.396/( ( (133.664 + max(-8.012, 0)) + (140.65 + max(-5.5, 0)) )/ 2 )
=11.396/( ( 133.664 + 140.65 )/ 2 )
=11.396/137.157
=8.31 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.355 + 2.127 + 0) - (17.494 + 0 + 3.5527136788005E-15)
=-8.012

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.157 + 2.081 + 0) - (14.738 + 0 + 0)
=-5.5

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cengild Medical Bhd's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=13.756/197.726
=6.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cengild Medical Bhd EBIT Related Terms

Cengild Medical Bhd EBIT Historical Data

* Premium members only.

The historical data trend for Cengild Medical Bhd's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cengild Medical Bhd EBIT Chart

Cengild Medical Bhd Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial 14.69 12.96 18.11 17.33 18.39

Cengild Medical Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.92 3.43 3.90 3.58 2.85

XKLS:0243 vs HCA, THC, DVA: EBIT Comparison

For the Medical Care Facilities subindustry, Cengild Medical Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cengild Medical Bhd EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cengild Medical Bhd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cengild Medical Bhd's EV-to-EBIT falls into.


XKLS:0243
67GF Score
Cengild Medical Bhd XKLS:0243
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cengild Medical Bhd EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM13.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of RM13.76 Mil mean?
Cengild Medical Bhd (XKLS:0243) has a EBIT of RM13.76 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cengild Medical Bhd.
Is Cengild Medical Bhd's EBIT too high?
Cengild Medical Bhd's current EBIT is RM13.76 Mil. Overall, Cengild Medical Bhd has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cengild Medical Bhd's EBIT compare to HCA and THC?
Cengild Medical Bhd's EBIT of RM13.76 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cengild Medical Bhd. Cengild Medical Bhd's current EBIT is RM13.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cengild Medical Bhd stock overvalued right now?
Based on GuruFocus' analysis, Cengild Medical Bhd (XKLS:0243) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.29, compared to a current price of RM0.20 — trading 31% below its estimated fair value. The current EBIT is RM13.76 Mil. Cengild Medical Bhd's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cengild Medical Bhd (XKLS:0243), the current EBIT is RM13.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cengild Medical Bhd (XKLS:0243) Overvalued in 2026?

Based on GuruFocus' analysis, Cengild Medical Bhd stock appears to be undervalued. The current stock price of RM0.20 is trading 31% below its estimated GF Value™ of RM0.29. GuruFocus considers Cengild Medical Bhd to be Significantly Undervalued.

Key valuation signals for XKLS:0243:

  • EBIT: RM13.76 Mil
  • GF Value™: RM0.29 vs. price of RM0.20 (31% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the XKLS:0243 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cengild Medical Bhd Business Description

Address No.7, Jalan Kerinchi, Unit 2-3 & 2-4, Level 2, Nexus, Bangsar South, Kuala Lumpur, MYS, 59200
Cengild Medical Bhd is a healthcare service provider operating a medical centre specializing in the diagnosis and treatment of gastrointestinal-related diseases, oncology, gynecology services., liver diseases, and obesity. The company operates in Malaysia and has two reportable segments, Consultant Services and Medical Management Services. A substantial portion of the overall revenue is generated from its Medical Management Services segment.
67GF Score

Get the complete analysis for XKLS:0243

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.20
Price
RM0.29
GF Value